Investigational drug · Phase 3
Azetukalner
Also called: XEN1101
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
8 still active
All registered trials
9
Any phase or sponsor naming "Azetukalner"
First trial start
2019
Jan 30, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Azetukalner", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Onset Seizures
- Major Depressive Disorder
- Bipolar Disorder
- Bipolar Depression
- Bipolar I Disorder
- Bipolar II Disorder
- Focal Epilepsy
- Tonic-Clonic Seizures
- Primary Generalized Tonic-Clonic Seizures
Approved drugs for the same conditions: Epilepsy and seizures · Depression (major depressive disorder) · Bipolar disorder · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Azetukalner" as an intervention, largest first.
- An Open-label Study of XEN1101 in EpilepsyPivotal-lookingEnrolling by invitation
Xenon Pharmaceuticals Inc.Industry
NCT05718817 · 880 participants (planned) · Start Apr 25, 2023 · Primary completion Apr 2033
Drug: XEN1101 · For: Focal Epilepsy; Tonic-Clonic Seizures
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 153 sites in all
- An Open-Label Study of Azetukalner in Major Depressive DisorderPivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT06922110 · 460 participants (planned) · Start Mar 18, 2025 · Primary completion Jan 2027
Drug: Azetukalner · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Bryant, Arkansas; Little Rock, Arkansas · 71 sites in all
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07076407 · 450 participants (planned) · Start Jul 8, 2025 · Primary completion May 2027
Drug: Azetukalner; Placebo · For: Major Depressive Disorder
Sites: Dothan, Alabama; Huntsville, Alabama; Bentonville, Arkansas · 50 sites in all
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07172516 · 400 participants (planned) · Start Aug 8, 2025 · Primary completion Jun 2028
Drug: Azetukalner; Placebo · For: Bipolar Disorder; Bipolar Depression; Bipolar I Disorder and 1 more
Sites: Tucson, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 44 sites in all
- An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)Pivotal-lookingActive, not recruiting
Xenon Pharmaceuticals Inc.Industry
NCT07217860 · 400 participants (planned) · Start Oct 30, 2025 · Primary completion Jun 2029
Drug: Azetukalner · For: Bipolar Depression; Bipolar I Disorder; Bipolar Disorder and 1 more
Sites: Little Rock, Arkansas; Rogers, Arkansas; Bellflower, California · 20 sites in all
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresPivotal-lookingCompleted
Xenon Pharmaceuticals Inc.Industry
NCT05614063 · 380 participants · Start Nov 18, 2022 · Primary completion Jan 12, 2026
Drug: XEN1101; Placebo · For: Focal Onset Seizures
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 125 sites in all
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Pivotal-lookingRecruiting
Xenon Pharmaceuticals Inc.Industry
NCT05716100 · 360 participants (planned) · Start May 9, 2023 · Primary completion Jan 2028
Drug: XEN1101; Placebo · For: Focal Onset Seizures
Sites: Little Rock, Arkansas; Downey, California; Los Angeles, California · 103 sites in all
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderPivotal-lookingTerminated
Xenon Pharmaceuticals Inc.Industry
NCT06775379 · 357 participants · Start Dec 20, 2024 · Primary completion Oct 28, 2026
Drug: Azetukalner; Placebo · For: Major Depressive Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Rogers, Arkansas · 45 sites in all
- A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPivotal-lookingRecruiting
Xenon Pharmaceuticals Inc.Industry
NCT05667142 · 160 participants (planned) · Start Feb 14, 2023 · Primary completion Apr 2027
Drug: XEN1101; Placebo · For: Primary Generalized Tonic-Clonic Seizures
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 141 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial.
French JA, LaFrance WC, Ryvlin P, et al. · JAMA Neurol 2026
- Azetukalner in Adults With Focal Seizures: Research Summary.
· JAMA Neurol 2026
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Antiseizure Medications in Development: Novel Mechanisms, Precision Therapy, and the Move Towards Disease Modification.
Martins WA · Curr Issues Mol Biol 2026
- From Retigabine to Azetukalner: Reviving Voltage-Gated Potassium Channels for Epilepsy Therapy.
Rosendahl P, Schulig L, Link A · Arch Pharm (Weinheim) 2026
- KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers.
Lee IC, Yang SB, Wong SH, et al. · CNS Neurol Disord Drug Targets 2026
Also in development for Focal Onset Seizures
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.